Book a Meeting

PROTAC® Molecule

As an emerging therapeutic modality, PROTAC® technology belongs to the branch of targeted protein degradation (TPD) technology. The critical pathway of this technology is the ubiquitin-proteasome pathway, in which the misfolded, abnormal, unneeded or damaged proteins (the targets in PROTAC® molecules) are degraded. A PROTAC® molecule has good compatibility: two ligands and a linker are conjugated covalently and function well with each other as an intact molecule. Although powerful, there are technical challenges especially in the molecule design. Strategic variety encompassed in the combinations of linkers and ligands should be taken into consideration carefully. To save the research time, Creative Biolabs provides intact well-synthesized PROTAC® molecules. Customers could immediately start their drug discovery process with the products.

Our services are For Research Use Only. We do not provide direct services for patients.
dBET1(CAT#: PRLG-004)
Datasheet INQUIRY
Type: PROTAC® molecule
Size: 5 mg
Physical State: Lyophilized white powder

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    USA
  • Address:
  • Tel:
  • Fax:
  • Email:
    UK
  • Address:
  • Tel:
  • Email:
    Germany
  • Address:
  • Tel:
  • Email:
Social Media
PROTAC® is a registered trademark owned by Arvinas Operations, Inc.
Copyright © 2024 Creative Biolabs. All Rights Reserved.